Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 12/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683116 | 0.87 | CASP1 (0.59) | CASP1HTR2ASLC6A4KCNH2ALDH1A1 | |
| SCHEMBL5682849 | 0.81 | CASP1 (0.60) | CASP1ALDH1A1 | |
| SCHEMBL21970592 | 0.78 | CASP1 (0.52) | CASP1HTR2ASLC6A4KCNH2ALDH1A1 | |
| SCHEMBL5678964 | 0.77 | CASP1 (0.86) | CASP1 | |
| SCHEMBL5678951 | 0.76 | CASP1 (0.54) | CASP1HTR2ASLC6A4TRPV4SCN9A | |
| SCHEMBL5679392 | 0.74 | CASP1 (0.58) | CASP1HTR2ASLC6A4TRPV4ALDH1A1 | |
| SCHEMBL6249693 | 0.72 | CASP1 (0.51) | CASP1HTR2ASLC6A4TRPV4ALDH1A1 | |
| SCHEMBL5682969 | 0.72 | CASP1 (0.55) | CASP1HTR2ASLC6A4TRPV4ALDH1A1 | |
| SCHEMBL5680993 | 0.72 | CASP1 (0.47) | CASP1 | |
| SCHEMBL5682872 | 0.71 | GAA (0.53) | SLC6A4ALDH1A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0932600-B1 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6083981-A | USEFUL FOR TREATMENT OF STROKE, INFLAMMATORY DISEASES, SEPTIC SHOCK, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-6054487-A | ADMINISTERING AN INTERLEUKIN-ONE BETA CONVERTING ENZYME SUFFICIENT TO INHIBIT PRODUCTION OF GAMMA-INTERFERON | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |